EMEA-002367-PIP01-18

Key facts

Active substance
Anti-alpha synuclein monoclonal antibody (BIIB054)
Therapeutic area
Neurology
Decision number
P/0278/2018
PIP number
EMEA-002367-PIP01-18
Pharmaceutical form(s)
Solution for injection/infusion
Condition(s) / indication(s)
Treatment of Parkinson's disease
Route(s) of administration
Intravenous use
Contact for public enquiries
Biogen Idec Limited

Tel. +44 1628512586
E-mail: pip.enquiries@biogen.com

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating